Member Info for inanaco

Moljen ... cancer is the result of the failure of the immune system to clear defective cells ... the actually point of getting cancer is the "escape phase"
are you saying a replacement immune system is being trialed ... ? or an antibiotic type drug for defective self cells . ?

Bermuda You Posted

""""You can't compare the valuation of a company through market cap with the valuation achieved for the sale of IP, they're two completely different things. """""

Oh !!

I bow to your superior Knowledge ... even thou i have no idea what that means

as the valuation of any company must include its IP ...

Moljen its impossible to make T cells "obsolescent" they are the fundamental components of the adaptive immune system

Scancell does not "make t cells" ....... even BioNtech do not make T cells with TCR ...

we only mess about with "binding"

rather than speculating on the maths ........... why not list them to create a list for us

"""All the small percentages put together add up""

https://www.loxooncology.com/docs/presentations/LOXO_SOHO_2018.PDF

so if an "unkown quantity" is worth $40m .............. why is scancell at 7p ....... ???

only read the Headline .........

Lilly's LOXO-305, bought from Redx for $40m last year in a transaction that rescued the company from financial oblivion, is said to be the sector's most selective non-covalent BTK inhibitor ""but the project is still something of an unknown quantity."""

Tf ........... """Science 100% yes""".

The rest is up for grabs.

LOL ..

what is the rest ?

every deal will be based around the science
every cash raise funds the science
all the trials are based around the science ...
every move the BOD make takes into account the science or the technology ...

you have left yourself a very small window ..

Bermuda ... Scancell is more than NSCLC

but it does show the value of Scancell ............ if a treatment that targets only 2% can command these sort of values

Its good news for those patients with RET altered cancer, Bermuda but we should stress it is a tiny % of NSCLC lung cancer patients

forgot to reply to this bit ...........

You, me and K all have the right to post our views equally do we not ?

yes ......... but if you post on here anyone has a right to cross examine that post to test authenticity and the test the authors understanding ... that is more of a problem for you, because you copy and paste other peoples posts from other BB's making it difficult to cross examine the author's understanding ending with a complex cross board debate. So you do not add value by this process you actually create more issues ... Considering the author has the option to post on both BB's

exactly who is Inan ..

point being ... the power of research does not come from Me ... or knowlesi .. but from our Scientists

all i do, is try and explain it, and look for failure points .. which is why you have now an extra process added to the Moditope TCR .... did Knowlesi find that "missing process" did Bermuda ?????

make that simple for you ...........

I found a possible failure point of the collaboration, you cannot call me Team Ramp ...
its now sorted as per My previous Posts ...

but at least YOU know who i am ... and my track record in the commercial world .. !!

so again ... who is knowlesi ... what evidence has he presented as a post that gives him some sort of "credibility" on the subject of Scancell ...

indeed what post of ""yours"" fits into that category of actually being able to question my understanding ???

but that is your problem ...

the problem is how do you explain the immune system is an orchestra that can play out of tune ...

Because Cancer is """""Disorders of the immune system"""" that is why its such a Huge opportunity for scancell

which is why its called the "escape phase"

The immune surveillance theory

in answer to A = No
in answer to B = No
the immunobody route of engaging CD4/CD8 the adaptive system side could be enhanced by this Bi specific MAB route

wait the the trial results ... then we can look at how significant an improvement over existing PD-1 ... is given to the 4-1BB stimulation .. which would impart synergy to SCiB1/2

Only 13% have this gene, however for that 13% it may be very helpful if they can stall progression in 50% of the 13% it allows time to build an immune response with a vaccine and PD-1 ...

Wildforce ... more confident than ever

really don't know what this market is now waiting for ........

When Scancell’s anti-glycan mouse mAbs were humanised for clinical use they lost their ability to kill tumour cells directly. Scancell has now patent protected a technology platform (AvidiMab™) which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification reinstates the direct tumour cell killing ability of the anti-glycan humanised mAbs but could also be used to increase the potency of any human mAb and is available for licensing.

Scancell has identified homocitrullinated epitopes derived from several proteins, including vimentin, aldolase, cytokeratin 8, immunoglobulin binding protein (BiP), nucleophosmin (NPM), a-enolase, ß-catenin and heat shock protein (HSP-60),

"""""""""""all""""""""""""""" of which generate potent T cell responses in preclinical models. Evidence exists for all of these proteins having a link to a wide range of cancer types:

yes i did tell you that after you claimed Bio only make 5% on average

""Pfizer make between 19 and 26%. I think one year they showed 43% due to carried forward tax.""